Clinical outcome of febrile neutropenia in children with cancer using ceftazidime and aminoglycosides

Pediatric Hematology and Oncology

Volumn 24, Issue 8, 2007, Pages 595-606

  Laoprasopwattana, Kamolwish ^a,b   Pruekprasert, Pornpimol ^a   Laosombat, Vichai ^a   Wongchanchailert, Malai ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Aminoglycosides; Ceftazidime; Children; Fever; Neutropenia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPHOTERICIN B; ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; SULPERAZON;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CHILDHOOD CANCER; CONTROLLED STUDY; DEATH; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; SCHOOL CHILD; SECONDARY INFECTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; AMIKACIN; ANTI-BACTERIAL AGENTS; BACTEREMIA; CEFTAZIDIME; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GENTAMICINS; GUIDELINES AS TOPIC; HUMANS; IMIPENEM; INFANT; MALE; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 37349066132     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010701703636     Document Type: Article

References (37)

1. Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev. 2002:CD003038.
2. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2006;57:176-189.
3. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis. 1997;25:551-573.
4. Rolston KV, Berkey P, Bodey GP, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med. 1992;152:283-291.
5. Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med. 2004;140:26-32.
6. Lan CK, Hsueh PR, Wong WW, et al. Association of antibiotic utilization measures and reduced incidence of infections with extended-spectrum beta-lactamase-producing organisms. J Microbiol Immunol Infect. 2003;36:182-186.
7. Ariffin H, Navaratnam P, Mohamed M, et al. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. Int J Infect Dis. 2000;4:21-25.
8. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999;29:490-494.
9. Richard P, Amador Del Valle G, Moreau P, et al. Viridans streptococcal bacteraemia in patients with neutropenia. Lancet. 1995;345:1607-1609.
10. Jones RN. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis. 1999;29:495-502.
11. Maipang M, Wongchanchailert M, Laosombat V, Pruekprasert P. Fever and neutropenia in paediatric cancer patients. Songkla Med J. 1990;8:275-281.
12. Jittithaworn P, Preukprasert P. Febrile Neutropenia in Pediatric Cancer Patients. Thesis, Songkhla: Prince of Songkla University; 2003.
13. Junquera S, Loza E, Baquero F [Changes in the antimicrobial susceptibility of Escherichia coli isolates from nosocomial versus community-acquired urinary tract infections.] Enferm Infecc Microbiol Clin. 2005;23:197-201.
14. Riikonen P. Imipenem compared with ceftazidime plus vancomycin as initial therapy for fever in neutropenic children with cancer. Pediatr Infect Dis J. 1991;10:918-923.
15. Charnas R, Luthi AR, Ruch W. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children. Pediatr Infect Dis J. 1997;16:346-353.
16. Fanci R, Paci C, Martinez RL, et al. Management of fever in neutropenic patients with acute leukemia: current role of ceftazidime plus amikacin as empiric therapy. J Chemother. 2000;12:232-239.
17. Cometta A, Glauser MP. Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: a review. J Chemother. 1996;8:375-381.
18. Miranda-Novales MG, Belmont-Martinez L, Villasis-Keever MA, et al. Empirical antimicrobial therapy in pediatric patients with neutropenia and fever: risk factors for treatment failure. Arch Med Res. 1998;29:331-335.
19. Urabe A. Clinical features of the neutropenic host: definitions and initial evaluation. Clin Infect Dis. 2004;39(Suppl 1):S53-S55.
20. Donowitz GR, Maki DG, Crnich CJ, Pappas PG, Rolston KV. Infections in the neutropenic patient - new views of an old problem. Hematology Am Soc Hematol Educ Program. 2001:113-139.
21. Wust J, Frei R. Multicenter study of the in vitro activity of cefepime in comparison with five other broad-spectrum antibiotics against clinical isolates of gram-positive and gram-negative bacteria from hospitalized patients in Switzerland. Clin Microbiol Infect. 1999;5:262-269.
22. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med. 1988;148:2642-2645.
23. Elting LS, Rubenstein EB, Rolston K, et al. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol. 2000;18:3699-3706.
24. Jitsurong S, Yodsawat J. Prevalence of extended-spectrum beta-lactamases (ESBLs) produced in blood isolates of gram-negative bacteria in a teaching hospital in southern Thailand. Southeast Asian J Trop Med Public Health. 2006;37:131-135.
25. Rice LB, Eckstein EC, DeVente J, Shlaes DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis. 1996;23:118-124.
26. Mebis J, Goossens H, Bruyneel P, et al. Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients. Leukemia. 1998;12:1627-1629.
27. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004;39:31-37.
28. Fanci R, Paci C, Leoni F, Casini C, Longo G. Ticarcillin-clavulanic acid plus amikacin versus ceftazidime plus amikacin in the empirical treatment of fever in acute leukemia: a prospective randomized trial. J Chemother. 2003;15:253-259.
29. Erman M, Akova M, Akan H, et al. Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study. Scand J Infect Dis. 2001;33:827-831.
30. Corapcioglu F, Sarper N. Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost. Pediatr Hematol Oncol. 2005;22:59-70.
31. Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother. 1995;39:445-452.
32. Marie JP, Vekhoff A, Cony-Makhoul P, et al. [Piperacilline/tazobactam combination + amikacin versus ceftazidime + amikacin in patients with neutropenia and fever. An open multicenter study. Groupe d'etude des Aplasies Febriles.] Presse Med. 1995;24:397-401.
33. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother. 1996;40:1108-1115.
34. de la Camara R, Figuera A, Sureda A, et al. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study. Haematologica. 1997;82:668-675.
35. Behre G, Link H, Maschmeyer G, et al. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Ann Hematol. 1998;76:73-80.
36. Agaoglu L, Devecioglu O, Anak S, et al. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother. 2001;13:281-287.
37. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis. 2004;4:519-527.